242 related articles for article (PubMed ID: 21245757)
1. FLT3 inhibitors: a story of the old and the new.
Fathi A; Levis M
Curr Opin Hematol; 2011 Mar; 18(2):71-6. PubMed ID: 21245757
[TBL] [Abstract][Full Text] [Related]
2. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Fathi AT; Chabner BA
Oncologist; 2011; 16(8):1162-74. PubMed ID: 21765192
[TBL] [Abstract][Full Text] [Related]
3. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.
Kayser S; Levis MJ
Leuk Lymphoma; 2014 Feb; 55(2):243-55. PubMed ID: 23631653
[TBL] [Abstract][Full Text] [Related]
4. The role of quizartinib in the treatment of acute myeloid leukemia.
Ostronoff F; Estey E
Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
[TBL] [Abstract][Full Text] [Related]
5. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
Marensi V; Keeshan KR; MacEwan DJ
Biochem Pharmacol; 2021 Jan; 183():114348. PubMed ID: 33242449
[TBL] [Abstract][Full Text] [Related]
7. Will newer tyrosine kinase inhibitors have an impact in AML?
Levis MJ
Best Pract Res Clin Haematol; 2010 Dec; 23(4):489-94. PubMed ID: 21130412
[TBL] [Abstract][Full Text] [Related]
8. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
9. Availability of FLT3 inhibitors: how do we use them?
Perl AE
Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
[TBL] [Abstract][Full Text] [Related]
10. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
Knapper S
Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
[TBL] [Abstract][Full Text] [Related]
11. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
12. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
13. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
14. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Swords R; Freeman C; Giles F
Leukemia; 2012 Oct; 26(10):2176-85. PubMed ID: 22614177
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia.
Gebru MT; Atkinson JM; Young MM; Zhang L; Tang Z; Liu Z; Lu P; Dower CM; Chen L; Annageldiyev C; Sharma A; Imamura Kawasawa Y; Zhao Z; Miller BA; Claxton DF; Wang HG
Blood; 2020 Aug; 136(9):1067-1079. PubMed ID: 32396937
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo.
Xu Y; Wang NY; Song XJ; Lei Q; Ye TH; You XY; Zuo WQ; Xia Y; Zhang LD; Yu LT
Bioorg Med Chem; 2015 Aug; 23(15):4333-4343. PubMed ID: 26142317
[TBL] [Abstract][Full Text] [Related]
17. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
Smith CC; Shah NP
Am Soc Clin Oncol Educ Book; 2013; ():313-8. PubMed ID: 23714533
[TBL] [Abstract][Full Text] [Related]
18. FLT3 inhibition as a targeted therapy for acute myeloid leukemia.
Sanz M; Burnett A; Lo-Coco F; Löwenberg B
Curr Opin Oncol; 2009 Nov; 21(6):594-600. PubMed ID: 19684517
[TBL] [Abstract][Full Text] [Related]
19. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
Langdon WY
Crit Rev Oncog; 2012; 17(2):199-209. PubMed ID: 22471708
[TBL] [Abstract][Full Text] [Related]
20.
Naqvi K; Ravandi F
Leuk Lymphoma; 2019 Aug; 60(8):1866-1876. PubMed ID: 30997851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
